Results 1 to 10 of about 3,127,180 (269)

An Overview of the Evolution of the Genus Astragalus (Fabaceae) in the Old World‎ [PDF]

تاکسونومی و بیوسیستماتیک, 2022
In the present study, the trend of divergence and fragmentation of different sections of Astragalus in the Old World has been investigated. Based on previous studies, Astragalus species are divided into three groups: primitive, intermediate, and advanced.
Ali Asghar Maassoumi, Parvaneh Ashouri, Farzaneh Khajoei Nasab   +2 more
doaj   +1 more source

Efficacy and safety of camrelizumab combined with albumin-bound paclitaxel as third- or later-line regimen in patients with advanced non-small cell lung cancer

Frontiers in Immunology, 2023
BackgroundThe clinical efficacy and safety of camrelizumab as a third- or later-line regimen in patients with advanced non-small cell lung cancer (NSCLC) have not been determined in large clinical trials.ObjectiveThis study aimed to evaluate the clinical
Jianfeng Zhu, Yanyan Yu, Jiaqi Mei, Shiyao Chen, Jiufei Li, Sicong Jiang   +5 more
doaj   +1 more source

Immunotherapy and Its Timing in Advanced Basal Cell Carcinoma Treatment

Dermatology Practical & Conceptual, 2023
For patients with advanced BCC, including locally advanced or metastatic BCC not amenable to curative surgery or radiotherapy, hedgehog pathway inhibitors (HHI) vismodegib and sonidegib are approved as first-line systemic treatment.
Clio Dessinioti, Alexander Stratigos
doaj   +1 more source

First-Generation EGFR-TKI Plus Chemotherapy Versus EGFR-TKI Alone as First-Line Treatment in Advanced NSCLC With EGFR Activating Mutation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Frontiers in Oncology, 2021
ObjectiveThe aim of this meta-analysis was to evaluate efficacy and toxicity of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) in combination with chemotherapy (CT) compared to EGFR-TKI monotherapy as first-line treatment in ...
Qiang Wu, Wuxia Luo, Wen Li, Ting Wang, Lin Huang, Feng Xu   +5 more
doaj   +1 more source

Second-Line Chemotherapy in Advanced Non-Small Cell Lung Cancer (NSCLC): Single Institution Experience [PDF]

Research in Oncology, 2017
Background: Lung cancer is the leading cause of cancer-related death worldwide. Non-small cell lung cancer (NSCLC) accounts for 80-85 %.Methods: In this retrospective hospital based study, 424 NSCLC patients "stage IIIb-IV" were enrolled to analyze the ...
Hanaa Attia, Noha Y. Ibrahim, Soha Talima, Ibrahim Elhassan   +3 more
doaj   +1 more source

Long-Term Efficacy of Neoadjuvant Concurrent Chemoradiotherapy for Potentially Resectable Advanced Siewert Type II and III Adenocarcinomas of the Esophagogastric Junction

Frontiers in Oncology, 2021
BackgroundReports have shown that neoadjuvant concurrent chemoradiotherapy (nCRT) increases the R0 resection rate for patients with Siewert type II or III adenocarcinoma of the gastroesophageal junction (AEG).
Yuan Tian, Jun Wang, Xueying Qiao, Jun Zhang, Yong Li, Liqiao Fan, Zhidong Zhang, Xuefeng Zhao, Bibo Tan, Dong Wang, Peigang Yang, Qun Zhao   +11 more
doaj   +1 more source

Genome editing for vegetable crop improvement: Challenges and future prospects

Frontiers in Genetics, 2022
Vegetable crops are known as protective foods due to their potential role in a balanced human diet, especially for vegetarians as they are a rich source of vitamins and minerals along with dietary fibers.
Ruma Devi, Shivani Chauhan, Tarsem Singh Dhillon   +2 more
doaj   +1 more source

Six-Month Effectiveness of Advanced vs. Standard Hybrid Closed-Loop System in Children and Adolescents With Type 1 Diabetes Mellitus

Frontiers in Endocrinology, 2021
IntroductionThe purpose of this study was to assess the effectiveness of advanced- (a-HCL) vs. standard-hybrid closed-loop (s-HCL) systems use up to 6 months of treatment in a real-world setting of children and adolescents with T1DM.MethodsWe ...
Gianluca Tornese, Francesca Buzzurro, Claudia Carletti, Elena Faleschini, Egidio Barbi, Egidio Barbi   +5 more
doaj   +1 more source

Phase 2 randomized controlled trial of intravenous or intraperitoneal paclitaxel plus mFOLFOX6 vs. mFOLFOX6 as first-line treatment of advanced gastric cancer

Frontiers in Oncology, 2022
ObjectiveWe conducted a phase 2 trial to compare the safety and efficacy of intravenous paclitaxel or intraperitoneal paclitaxel plus mFOLFOX6 vs. mFOLFOX6 in untreated advanced gastric cancer.MethodsParticipants with untreated advanced gastric cancer ...
Shen Zhao, Shen Zhao, Liyu Su, Yigui Chen, Xiaofeng Li, Peicheng Lin, Wujin Chen, Wenzheng Fang, Jinfeng Zhu, Hui Li, Liping Ren, Jie Liu, Yanni Hong, Shaowei Lin, Nanfeng Fan, Rongbo Lin, Rongbo Lin   +16 more
doaj   +1 more source

Interstitial high-dose-rate brachytherapy in locally advanced and recurrent vulvar cancer

Journal of Contemporary Brachytherapy, 2016
Purpose : The aim of the study was to report our experience with high-dose-rate interstitial brachytherapy (HDR-ISBT) in locally advanced and recurrent vulvar cancer.
Sylwia Kellas-Ślęczka, Brygida Białas, Marek Fijałkowski, Piotr Wojcieszek, Marta Szlag, Agnieszka Cholewka, Maciej Ślęczka, Zofia Kołosza   +7 more
doaj   +1 more source